Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 34.90% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -9.94% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 7.32% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 46.81% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 27.85% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -98.15% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 111.22% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 4.87% |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 102.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.81% |
| Dec 31, 2025 | 39.52% |
| Sep 30, 2025 | 32.05% |
| Jun 30, 2025 | -9.61% |
| Mar 31, 2025 | 53.26% |
| Dec 31, 2024 | 286.50% |
| Sep 30, 2024 | 36.74% |
| Jun 30, 2024 | -14.46% |
| Mar 31, 2024 | 14.28% |
| Dec 31, 2023 | 9.33% |
| Sep 30, 2023 | 131.41% |
| Jun 30, 2023 | 14.74% |
| Mar 31, 2023 | -76.80% |
| Dec 31, 2022 | 13.62% |
| Sep 30, 2022 | 0.34% |
| Jun 30, 2022 | 29.09% |
| Mar 31, 2022 | 28.86% |
| Dec 31, 2021 | -56.35% |
| Sep 30, 2021 | -3.57% |
| Jun 30, 2021 | 71.44% |